Drug intelligence / Profile preview

PHENYLAMINOIMIDAZO(1,2-ALPHA)PYRIDINE

Development stage
Unknown
Modality
Small Molecules
01

Overview

PHENYLAMINOIMIDAZO(1,2-ALPHA)PYRIDINE is a synthetic small molecule with the molecular formula C20H14Cl2N4O3S. It belongs to the imidazo[1,2-a]pyridine class of compounds, which are recognized as a privileged scaffold in medicinal chemistry due to their diverse biological activities. While specific detailed mechanisms of action for this exact compound are not readily available, the broader class of imidazo[1,2-a]pyridine derivatives has been investigated for various pharmacological effects, including anticancer, antituberculosis, antibacterial, antiviral, anti-inflammatory, antidiabetic, and antiplasmodial properties. Some derivatives have been shown to inhibit targets such as CDK, VEGFR, PI3K, EGFR, RGGT, and act as CXCR4 receptor antagonists, or ligands for the 18-kDa translocator protein (TSPO). This compound is classified as a pharmaceutical.

Other names
4-((6-(2,6-dichlorobenzoyl)imidazo(1,2-a)pyridin-2-yl)amino)benzene-1-sulfonamide4-{[6-(2,6-dichlorobenzoyl)imidazo[1,2-a]pyridin-2-yl]amino}benzene-1-sulfonamideRefChem:8617124-{[6-(2,6-Dichlorobenzoyl)imidazo[1,2-A]pyridin-2-Yl]amino}benzenesulfonamide1ykraminoimidazo[1,2-a]pyridine deriv. 2iBDBM6670BDBM-6670BDBM 6670SCHEMBL29941627SCHEMBL-29941627SCHEMBL 29941627NS00070764NS-00070764NS 00070764Q27095345Q-27095345Q 270953454-({6-[(2,6-dichlorophenyl)carbonyl]imidazo[1,2-a]pyridin-2-yl}amino)benzene-1-sulfonamide4-({6-[(2,6-dichlorophenyl)carbonyl]imidazo[1,2-a]pyridin-2-yl}amino)benzenesulfonamide
02

Targets

CDK2 (Cyclin-dependent kinase 2)

Beyond the preview

Go deeper on PHENYLAMINOIMIDAZO(1,2-ALPHA)PYRIDINE.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on PHENYLAMINOIMIDAZO(1,2-ALPHA)PYRIDINE.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call